suggests that there had been significantly more past infection with HAV among new donors in West Scotland than in North London, though a history of past jaundice was more common among the latter; in North London 3·6% (n=1876) of British born new donors had a history of jaundice and in West Scotland 2·6% (n=7460). These differences may have resulted from more inapparent childhood infections among the Scottish donors.

In our series of 2000 new donors there were 124 who had been born abroad in countries where HAV infections are more common than they are in Britain. Only 5 gave a history of jaundice, but 72% had anti-HAV (n=50). Their average anti-HAV titre was four-fold lower than that of British born JH donors with antibody. The few histories of jaundice and the low anti-HAV titres among donors born abroad suggest that many may have been infected in infancy or childhood.

Much of the immunoglobulin prepared in the U.K. is given for hepatitis A prophylaxis to people going to work abroad in countries where HAV infection is common. A higher titre immunoglobulin which would protect for longer or might be given in smaller doses could be made from the plasma of donors selected simply on the basis of a past history of jaundice; we would expect this globulin to be at least two-fold higher in anti-HAV titre than that made from unselected donors.

Department of Microbiology,
Middlesex Hospital Medical School,
London W1P 7LD

R. S. TEDDER
C. H. CAMERON

North London Blood Transfusion Centre,
Edgware

J. A. J. BARBARA
D. HOWELL

BLOOD DONORS WITH HISTORY OF JAUNDICE

SIR,—The former policy of the Scottish Blood Transfusion Service was to reject as donors all persons admitting a history of jaundice. Lately this policy has been modified to exclude only would-be donors with a history of jaundice within the previous twelve months: donations are now accepted from most persons with a history of jaundice, provided they are HB_sAg negative upon routine testing.

We investigated the prevalence of HB_sAg in 9257 new (previously untested) donors with and without a history of jaundice. The attempt was made to include in the "jaundice" category only those donors who had a clear recollection of having had clinical jaundice or definite hepatitis: a history of neonatal jaundice was not included in this category. Donors whose jaundice episode had occurred later than 1971 were sent a detailed questionnaire seeking evidence of an episode of hepatitis B, and hospital and general practice records were consulted where possible. Further information was obtained on 36 of the 45 donors in this group.

HB_sAg was detected in 12 new blood-donors—1 out of the 792 with a history of jaundice plus 18 out of 8467 with no such history. The single HB_sAg positive donor among those with a history of jaundice was a drug addict, known to his GP to be a carrier. Of the 36 donors who were followed up, 16 gave a history strongly suggestive of viral hepatitis, but in only 6 was it possible to obtain the results of HB_sAg testing at the time of illness: all were negative. These findings show that in this community a history of jaundice does not define a group with a high prevalence of HB_sAg carriage.

A study in the West of Scotland[1] found a slightly higher HB_sAg carrier rate (1·6 times higher) among donors with a history of jaundice than among those with no such history. However, new and previously screened donors were included and this may have underestimated the differences between the two groups. A report from Manchester[2] found approximately three times as many HB_sAg carriers among 2561 new donors with a history of jaundice when compared with 38 333 new donors with no history of jaundice. The RPHA 'Hepatest' assay was used in the Manchester study, while we used a more sensitive RIA system[3] so that the true difference in HB_sAg prevalence may be greater in the two populations than the data suggest. The explanation for these differing results probably lies in the characteristics of the different local populations.

We conclude that in the donor population of South-East Scotland a history of jaundice is not associated with an increased risk of HBsAg carriage. This is in agreement with findings in the West of Scotland[3] reported by Dr Follett and colleagues (Feb. 2, p. 246). The prevalence of antibody to hepatitis A in our region is similar in donors with and without a history of jaundice (84% and 78%, respectively). This suggests that the viruses of "non-A, non-B hepatitis" may be a significant cause of jaundice in this population.

Edinburgh and South-East Scotland
Regional Blood Transfusion Centre,
Royal Infirmary,
Edinburgh EH3 9HB

R. HOPKINS
A. E. ROBERTSON
A. RAVIE
D. B. L. MCCLELLAND

TISSUE CEA TEST IN ENDOCERVICAL AND ENDOMETRIAL ADENOCARCINOMA

SIR,—Dr Wahlström and his colleagues (Dec. 1, p. 1159), in their study with immunoperoxidase staining for carcinoembryonic antigen (CEA), found that 80% of endocervical tumours were CEA positive while only 8% of endometrial tumours contained CEA. By eliminating endocervical clear-cell tumours and adenosquamous tumours of the endometrium, they improved their results to 80% of endocervical tumours and 0% of endometrial tumours. They concluded that the CEA test would prove valuable in the routine distinction of these two tumours.

The usefulness of this test is questionable, however, when one considers the incidences of endometrial and endocervical adenocarcinoma. Endocervical carcinoma represents approximately 10% of all cases of invasive cervical carcinoma.[5] Some 1600 cases per year are seen in the United States, while the corresponding figure for endometrial carcinoma is 37 000.[5] On Wahlström's figures 80% (i.e., 1280) of the endocervical tumours would be CEA positive (true positive, TP) while 8% (or 2960) endometrial tumours would be CEA positive (false positive, FP). On Galen's formula[6] (TP÷[TP+FP]), the predictive value of diagnosing a tumour as endocervical on the basis of a positive CEA stain would be only 30%. Similar results can be obtained using standard histochemical stains for mucin since 72% of endocervical carcinomas are mucin positive,[7] while only 5% of endometrial tumours contain stainable mucin.[8] Excluding both clear cell and adenosquamous tumours would, while decreasing the number of false positive results, eliminate most cases where the site of origin is often difficult to establish.

In view of the expense of immunoperoxidase staining, the carcinogenicity of the benzidine dyes used in most immunoperoxidase methods, and the lack of predictive power, immuno-

1. Crawford RJ, Barr A, MacTavish I, Dow BC, Mitchell R. Blood donors with a history of jaundice. *Lancet* 1979; ii: 155.
2. Renton PH, Roach DG, Stratton F. Blood donors with a history of jaundice. *Lancet* 1978; ii: 833.
3. Hopkins R, Ross S, Jordan T, Watt AD. Improved economies of HBsAg screening with commercial radioimmunoassay reagents. *J Clin Pathol.* 1980; **33**: 19.
4. Gallup DG, Abell MR. Invasive adenocarcinoma of the uterine cervix. *Obstet Gynecol* 1977; **49**: 596–603.
5. American Cancer Society. Cancer statistics 1979 *Ca* 1979; **29**: 14.
6. Galen RS, Gambino SR. Beyond normality: The predictive value and efficiency of medical diagnosis. New York: John Wiley, 1975.
7. Haggard JL, Cotten N, Dougherty CM, Mickal A. Primary adenocarcinoma of the cervix. *Obstet Gynecol* 1964; **24**: 183–93.
8. Demopolous RI. Carcinoma of the endometrium. In: Blaustein A, ed Pathology of the female genital tract. New York: Springer, 1977: 281.